Literature DB >> 28287342

Bridging data across studies using frequentist and Bayesian estimation.

Teng Zhang1, Ilya Lipkovich2, Olga Marchenko2.   

Abstract

In drug development programs, an experimental treatment is evaluated across different populations and/or disease types using multiple studies conducted in countries around the world. In order to show the efficacy and safety in a specific population, a bridging study may be required. There are therapeutic areas for which enrolling patients to a trial is very challenging. Therefore, it is of interest to utilize the available historical information from previous studies. However, treatment effect may vary across different subpopulations/disease types; therefore, directly utilizing outcomes from historical studies may result in a biased estimation of treatment effect under investigation in the target trial. In this article, we propose novel approaches using both frequentist and Bayesian frameworks that allow borrowing information from historical studies while accounting for relevant patient's covariates via a propensity-based weighting. We evaluate the operating characteristics of the proposed methods in a simulation study and demonstrate that under certain conditions these methods may lead to improved estimation of a treatment effect.

Entities:  

Keywords:  Bayesian analysis; bridging; clinical trials; power prior; propensity

Mesh:

Year:  2017        PMID: 28287342     DOI: 10.1080/10543406.2017.1289948

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  1 in total

1.  Bridging across patient subgroups in phase I oncology trials that incorporate animal data.

Authors:  Haiyan Zheng; Lisa V Hampson; Thomas Jaki
Journal:  Stat Methods Med Res       Date:  2021-01-27       Impact factor: 3.021

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.